Presentations will focus on the unique challenges of working with CSCs, from characterizing cell populations to the development of screening assays, identification of druggable targets and pathways, validation in pre-clinical models, and translation to the clinic.
CHI just confirmed the participation of Dr. John S. Yu (Cedars-Sinai Medical Center / ImmunoCellular Therapeutics)
Dr. Yu is a member of the full-time faculty in the Department of Neurosurgery at Cedars-Sinai Medical Center. An internationally renowned neurosurgeon, Dr. Yu's clinical focus is on the treatment of malignant and benign brain and spinal tumors. He is also conducting extensive research in immune and gene therapy for brain tumors. He has also done extensive research in the use of neural stem cells as delivery vehicles for brain cancers and neurodegenerative diseases. He was inducted into Castle and Connelly's America's Top Doctors in 2005. Dr. Yu has published articles in a number of prestigious journals, including The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science and Journal of Neurosurgery.
Additional companies presenting:
Cellerant Therapeutics, Inc.
Dainippon Sumitomo Pharma Group
The Mount Sinai School of Medicine
Sanford Consortium for Regenerative Medicine & Moores UC San Diego Cancer Center
University of California Los Angeles
University of Michigan Comprehensive Cancer Center
University of Texas Southwestern Medical Center
To view the agenda and to register, please visit http://www.TriConference.com/
About Cambridge Healthtech Institute (www.chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
Cambridge Healthtech Institute